Pathway Bioventures

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting the KCC2, a key mediator of inhibition in the brain. The company leverages groundbreaking research from institutions such as Boston Children’s Hospital, Harvard, and Laval University to create a proprietary neuron-specific K-Cl cotransporter discovery engine. This innovative platform aims to enhance the treatment of various conditions, including epilepsy, pain, and other central nervous system pathologies, by fine-tuning neuronal inhibition. Through its efforts, Axonis Therapeutics seeks to contribute to the healthcare industry's ability to combat neurodegeneration, restore neuronal excitation, and promote neuron regeneration, ultimately improving the quality of life for individuals affected by these disorders.

Modifi Biosciences specializes in direct DNA modification and the development of innovative cancer therapeutics. The company focuses on a unique strategy that involves altering tumor DNA to make cancer cells irreparable, while ensuring that healthy cells remain unharmed. This approach allows researchers to challenge and advance traditional methods of oncology drug development, potentially leading to more effective treatments for a variety of cancers. By exploiting DNA defects found in cancer cells, Modifi Biosciences aims to contribute significantly to the field of cancer research and therapy.

Afference is an electronics manufacturing company specializing in wearable technology that bridges the gap between the digital and physical worlds. The company has developed a haptic glove that utilizes neural stimulation to simulate the sensation of touch, allowing users to engage with 3D digital content and immersive environments. This innovative device is designed for various applications, including extended reality, gaming, and entertainment, enabling users to interact freely and realistically within digital spaces. Through its advanced technology, Afference aims to enhance the user experience by providing a tactile connection that enriches digital interactions.

IpiNovyx Bio is a biopharmaceutical company focused on creating a novel platform of immunoproteasome-modulating therapeutics aimed at improving the treatment of autoimmune and inflammatory diseases. The company's innovative approach involves developing inhibitors that selectively target the immunoproteasome, which plays a critical role in regulating specific immune cell types. By modulating these immune responses, IpiNovyx Bio seeks to enable patients to recover more effectively from their conditions and enhance their overall health.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

CytoVale, Inc. is a medical technology company based in San Francisco, California, that specializes in developing innovative biomarkers utilizing the mechanical properties of individual cells, a field known as mechanomics. Founded in 2013, the company employs microfluidics technology to effectively route and physically probe single cells, allowing for the simultaneous measurement of multiple biomarkers. This approach aims to enhance early detection and diagnosis of immune-mediated diseases, particularly sepsis. By leveraging cell mechanics and machine learning, CytoVale seeks to revolutionize the diagnostic landscape, ultimately improving patient outcomes and reducing treatment costs in healthcare.

Dimension Inx Corp., established in 2016 and based in Chicago, Illinois, specializes in designing and developing advanced biomaterials for research and commercial applications. The company focuses on creating three-dimensional (3D) printable materials and objects that mimic natural tissues, aiming to restore tissue and organ function. Dimension Inx's portfolio includes products such as Hyperelastic bone, 3D graphene, fluffy-x, and tissue papers, all designed to facilitate regenerative medicine and medical device applications. The company's unique biomaterials platform considers the intricate interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body, enabling clinicians to promote self-healing without resorting to organ transplantation.

miRecule, Inc. is a biotechnology company focused on developing innovative therapies for cancer and muscular dystrophy through its proprietary microRNA-based drug discovery platform, DREAmiR. Founded in 2016 and based in Gaithersburg, Maryland, the company leverages genomic and outcome data from thousands of patients to identify genetic abnormalities associated with diseases. This platform integrates genomic sequencing, expression, and prognostic data to identify candidates for microRNA replacement therapy, enabling the creation of tailored RNA therapeutics that can directly target and rectify these genetic issues. miRecule's research is aimed at developing first-in-class therapies, with current lead programs addressing Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy. Through its advanced approach, miRecule aims to provide solutions that help patients overcome the debilitating effects of their conditions.

Simergent, LLC is a manufacturer of automated peritoneal dialysis devices, established in 2014 and headquartered in Oklahoma City, Oklahoma, with an additional presence in Chicago, Illinois. The company focuses on developing affordable home dialysis solutions for both developed and emerging markets. Its innovative device is designed to be cost-effective and user-friendly, featuring a disposable tubing set that operates independently to troubleshoot issues. This enables patients to maintain a normal lifestyle and engage socially with family and friends while undergoing treatment at home, thereby enhancing their quality of life.

Scioto Biosciences, founded in 2017 and headquartered in Indianapolis, Indiana, specializes in the development of an Activated Bacterial Therapeutics (ABT) platform. This platform enables the delivery of live, active therapeutic bacteria to the gut, allowing them to persist and adhere to intestinal mucosa. The company's focus is on advancing microbiome therapeutics for various diseases associated with the central nervous system and gastrointestinal tract, aiming to enhance healing through its synbiotic-activated formulation.